Who is sponsoring NCT03005639?

NCT03005639 is sponsored by Inova Health Care Services.

What drugs are being tested in NCT03005639?

Interventions in NCT03005639: Vemurafenib and Cobimetinib.

What condition does NCT03005639 study?

NCT03005639 studies Stage IIIB-C Melanoma.

Is NCT03005639 still recruiting?

NCT03005639 is currently withdrawn. Last updated 9 May 2018.

Last reviewed 2018-05-09 · How we verify

NCT03005639

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Withdrawn Phase 2 Last updated 9 May 2018

What this trial tests

Phase 2 trial testing Vemurafenib and Cobimetinib in Stage IIIB-C Melanoma. Withdrawn.

Timeline

1 June 2017

Primary endpoint
24 February 2018

24 February 2018

Quick facts

Lead sponsor	Inova Health Care Services
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 June 2017
Primary completion	24 February 2018
Estimated completion	24 February 2018
Sites	1 location across United States

Drugs / interventions tested

Vemurafenib and Cobimetinib (vemurafenib-and-cobimetinib) — full drug profile →

Conditions studied

Stage IIIB-C Melanoma — all drugs for Stage IIIB-C Melanoma →

Sponsor

Inova Health Care Services — full company profile →

Who can join

18 and older, any sex, with Stage IIIB-C Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma • To evaluate the overall radiological complete response rate in patients with stage IIIB/C melanoma after 8 weeks of neoadjuvant vemurafenib and cobimetinib

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vemurafenib and Cobimetinib

Trials testing the same drug.

NCT02693535 — TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumo · Phase 2 · recruiting

Other Inova Health Care Services trials

Trials by the same sponsor.

NCT06564207 — Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults · Phase 2 · not yet recruiting
NCT07167199 — Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery · NA · not yet recruiting
NCT07437339 — Volume Reduction for Open Fracture Irrigation · Phase 4 · recruiting
NCT07485322 — Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center · NA · not yet recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03005639 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inova Health Care Services
Last refreshed: 9 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03005639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing